Currently, immunotherapy is attracting a lot of attention and may potentially become a
leading approach in the treatment of cancer. One emerging therapeutic, the chimeric …

Cancer immunotherapies have significantly improved patient survival and treatment options
in recent years. Nonetheless, the success of immunotherapy is limited to certain cancer …

Chimeric antigen receptor (CAR) T-cell therapy is an emerging immunotherapy against
several malignancies including glioblastoma, the most common and most aggressive …

Background Patients with relapsed/refractory acute myeloid leukaemia (AML) with FMS-like
tyrosine kinase 3-internal tandem duplication (FLT3-ITD) have limited treatment options and …

Simple Summary This review aims at analyzing an emergent topic regarding the possible
combined use of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), anticancer drugs …

Glioblastoma, formerly known as glioblastoma multiforme (GBM), is the most frequent and
most aggressive brain tumour in adults. The brain is an immunopriviledged organ, and the …

Acute Myeloid Leukemia (AML) is the most common acute leukemia affecting adults
characterized by the accumulation of immature myeloblasts in the marrow or peripheral …

Chimeric antigen receptors (CARs) are genetically engineered proteins that combine an
extracellular antigen-specific recognition domain with one or several intracellular T-cell …

Chemotherapy resistance and relapse remain significant sources of mortality for children
and adults with acute myeloid leukemia (AML). Further intensification of conventional …

Significant improvements in the survival of patients with hematological cancers following
hematopoietic stem cell transplantation provide evidence supporting the potency of immune …